Development and validation of immunoassays for novel immunotherapy drugs such as KEYTRUDA (pembrolizumab), OPDIVO (nivolumab) and YERVOY (ipilimumab), for monitoring drug levels in patients with lung cancer and malignant melanoma.
Developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases. These assays are used in the clinical routine and in several ongoing clinical trials.
Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
Late effects after testicular cancer; thyroid and kidney function, in collaboration with National Advisory Unit on Late Effects after Cancer Treatment.
Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).
Part of the collaboration study “Hallmarks in lung cancer”; validating different markers for potential development of assays clinically useful indaily practice.
Investigating the potential effect of combinatorial treatment of melanoma with PLX4032 (vemurafenib) and HER antibodies (in vitro studies).
Validating immunoassays for human epidermal growth factor receptors 2, 3 and 4 as tumour markers for HER2 positive breast cancer.
Recent publications
Gehin JE, Klaasen RA, Norli ES, Warren DJ, Syversen SW, Goll GL, Bjøro T, Kvien TK, Mjaavatten MD, Bolstad N(2021) Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort Rheumatol Int(in press) DOI 10.1007/s00296-021-04865-9, PubMed 33944985
Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune Tet al.(2021) Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial JAMA, 325(17), 1744-1754 DOI 10.1001/jama.2021.4172, PubMed 33944876
Köksal H, Baken E, Warren DJ, Løset GÅ, Inderberg EM, Wälchli S(2019) Chimeric antigen receptor preparation from hybridoma to T-cell expression Antib Ther, 2(2), 56-63 DOI 10.1093/abt/tbz007, PubMed 33928223